A study on the enrollment of patients with gastric cancer in Renqing Changjue's gastric cancer registry

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025000735

Enrollment

Unknown

Registered

2025-04-14

Start date

2024-06-04

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Renqing Changjue medication group:Renqing Changjue

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Pathologically confirmed primary gastric cancer; (2) Age: 18~75 years old gender is not limited; (3) Chemotherapy/immunotherapy/targeted therapy drugs were used as recorded; (4) Laboratory data: blood routine: total white blood cells =3.5×109/L; neutrophils =1.5×109/L; platelet count =100×109/L; hemoglobin =90g/L; liver and kidney function: total bilirubin =1.5×ULN; AST (SGOT) ALT (SGPT) =2.5×ULN; serum creatinine =1.5×ULN; (5) Good compliance; subjects agreed not to participate in other intervention studies during the treatment period; (6) The informed consent process was in accordance with the regulations and the informed consent form was signed by the person/legal representative.

Exclusion criteria

Exclusion criteria: (1) Patients with mental illness; (2) Patients with severe bleeding or systemic infection; (3) Patients with combination of other primary tumors or with significant bone marrow invasion and brain metastasis; (4) Significant traumatic damage such as surgical treatment in the last month; (5) Combination of severe cardiovascular system complications cerebrovascular system complications active hepatitis severe liver renal function abnormalities; (6) Have intestinal obstruction that cannot be treated with oral medication and requires intravenous high-energy nutrition; (7) Suffering from severe malabsorption or other diseases that affect gastrointestinal absorption; (8) The researcher considers that the inclusion is not appropriate.

Design outcomes

Primary

Measure	Time frame
EORTC-QLQ-C30;	—

Secondary

Measure	Time frame
MDASI-GI;	—

Countries

China

Contacts

Public ContactXu Yun

Medical Ethics Committee of Xiyuan Hospital China Academy of Chinese Medical Sciences

xyxiao78@163.com15210775378

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026